| __timestamp | Halozyme Therapeutics, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 11606000000 |
| Thursday, January 1, 2015 | 40028000 | 10313000000 |
| Friday, January 1, 2016 | 45853000 | 9762000000 |
| Sunday, January 1, 2017 | 53816000 | 9830000000 |
| Monday, January 1, 2018 | 60804000 | 10102000000 |
| Tuesday, January 1, 2019 | 77252000 | 10615000000 |
| Wednesday, January 1, 2020 | 45736000 | 8955000000 |
| Friday, January 1, 2021 | 50323000 | 9634000000 |
| Saturday, January 1, 2022 | 143526000 | 10042000000 |
| Sunday, January 1, 2023 | 149182000 | 10504000000 |
| Monday, January 1, 2024 | 154335000 |
Unlocking the unknown
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This chart compares the SG&A expenses of Merck & Co., Inc. and Halozyme Therapeutics, Inc. from 2014 to 2023.
Merck, a global leader, consistently reported SG&A expenses in the range of $9.0 billion to $11.6 billion annually. Despite fluctuations, Merck's expenses remained relatively stable, reflecting its robust operational strategies. In contrast, Halozyme, a smaller biotech firm, saw its SG&A expenses grow significantly, from $35.9 million in 2014 to $149.2 million in 2023, marking a staggering 315% increase.
This divergence highlights the different scales and growth trajectories of these companies. While Merck's expenses are indicative of its established market presence, Halozyme's rising costs suggest aggressive expansion and investment in its operations.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.